This year, oncology practices across the country are implementing changes to comply with the Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA), which will transition practices from the current fee-for-service reimbursement system to providing value-based cancer care.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Groups of 25 or more eligible clinicians participating in the Merit-based Incentive Payment System (MIPS) track of the Quality Payment Program (QPP) that intend to use the MIPS Group Web Interface and/or administer the Consumer Assessment of Healthcare Providers and Systems (CAHPS) for MIPS survey must register with the Centers for Medicare & Medicaid Services (CMS) by June 30, 2017. No other MIPS participants are required to register.
ASCO recently joined more than 180 patient and provider advocacy groups in signing a letter to the Medicare Payment Advisory Commission (MedPAC), urging the congressional advisory group to reconsider proposed changes to Medicare Part B drug reimbursement.
The American Society of Clinical Oncology (ASCO) opposes payer-imposed utilization management policies that restrict patient access to high-quality, high-value cancer care. In a statement released today, ASCO asserts that in modern cancer care there is frequently a lack of interchangeable clinical options, and that optimal cancer care requires patient access to the most medically appropriate drug at the most opportune time based on the highest quality evidence.
The Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act, launched in January 2017 and is being implemented in oncology practices across the country. 2017 is a transition year, but practices still have to report some quality data in order to avoid financial penalties in 2019. This transition year offers practices an opportunity to test the QPP reporting system before 2018, when quality reporting will require a significantly heavier lift to avoid financial penalties in 2020. ASCO is releasing a series of webinars to guide oncology practices to successful quality reporting.
The ASCO State Affiliate Council elected Elizabeth Blanchard, MD, Rahul Seth, DO, and Dave Dillahunt, MPA, CAE, to the State Affiliate Council’s Executive Subcommittee. The group is comprised of six physician members, one being the ASCO Board liaison, and two executive directors. The election was held during the Council’s spring meeting at ASCO in Alexandria, VA.
A new editorial in the Journal of Oncology Practice (JOP), “Making the Right Thing Easier to Do: Standardized Integration of Oncology and Palliative Care,” from Arif H. Kamal, MD, MBA, MHS, FAAHPM, expounds on a recent study that highlights the need for palliative care and the feasibility of its integration into a standard model of oncology care.
The U.S. Food and Drug Administration has permitted marketing of the Philips IntelliSite Pathology Solution (PIPS, Philips Medical Systems Nederland B.V.), as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue.
ASCO has endorsed Barbara McAneny, MD, FASCO, MACP, in her campaign for President-elect of the American Medical Association (AMA).
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategy (REMS) requirements for the use of Epogen/Procrit and Aranesp to treat patients with anemia due to associated myelosuppressive chemotherapy.
The U.S. Food and Drug Administration has granted marketing authorization to ipsogen JAK2 RGQ PCR Kit, manufactured by QIAGEN GmbH., to detect mutations affecting the Janus Tyrosine Kinase 2 (JAK2) gene. This is the first FDA-authorized test intended to help physicians in evaluating patients for suspected Polycythemia Vera (PV).
ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017-2018 ASCO Health Policy Fellowship program, now entering its second year.
On April 5, ASCO announced that Instituto de Oncologia do Vale (IOV) has become the first practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC. IOV is the second international practice to achieve this milestone in demonstrating the quality of care it provides to oncology patients.
On Friday, March 24, the U.S. House of Representatives withdrew H.R. 1628, the "American Health Care Act" (AHCA), which would have repealed and partly replaced the Affordable Care Act (ACA). House Members were unable to come to an agreement on enough key details to pass the bill.
CancerLinQ, LLC CEO, Kevin Fitzpatrick will join leaders of the cancer community including the Cancer Support Community and the American Cancer Society in speaking at the 2017 eyeforpharma Oncology Market Access & Pricing, taking place in Philadelphia.